Related Experiment Videos
Integrating Biomarkers and Hemodynamics for 1-Year Mortality Risk Stratification in Transcatheter Tricuspid
Christoph Edlinger1,2,3, Johannes Schlegl1,2, Marwin Bannehr1,2
1Department of Cardiology, Heart Center Brandenburg, Brandenburg Medical School Theodor Fontane (MHB), Bernau/Berlin, Germany.
Insights
New biomarkers, growth differentiation factor-15 (GDF-15) and soluble urokinase plasminogen activator receptor (suPAR), better predict mortality after transcatheter tricuspid interventions than NT-proBNP. Combining GDF-15 with right atrial pressure improves risk assessment.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomarkers
Background:
- Transcatheter tricuspid interventions are increasingly used for severe tricuspid regurgitation.
- Many patients present with advanced disease, limiting clinical benefit.
- Conventional biomarkers like NT-proBNP may not adequately reflect organ injury or right-sided hemodynamics.
Purpose of the Study:
- To evaluate if systemic biomarkers combined with invasive hemodynamic data improve risk stratification for 1-year mortality after transcatheter tricuspid intervention.
- To compare the prognostic accuracy of novel biomarkers (GDF-15, suPAR, H-FABP, sST2) against NT-proBNP.
Main Methods:
- Prospective, single-center cohort study of 100 patients undergoing transcatheter tricuspid intervention.
- Preprocedural assessment of biomarkers (GDF-15, suPAR, H-FABP, sST2, NT-proBNP) and right atrial (RA) pressure.
- Receiver operating characteristic (ROC) analyses to evaluate predictive performance for 1-year all-cause mortality.
Main Results:
- GDF-15 (AUC 0.795) and suPAR (AUC 0.746) showed the highest prognostic accuracy for 1-year mortality, outperforming NT-proBNP.
- Combining GDF-15 with RA pressure improved mortality prediction (AUC 0.805).
- Elevated GDF-15 or suPAR levels were associated with significantly reduced survival.
Conclusions:
- GDF-15 and suPAR are superior to NT-proBNP in predicting 1-year mortality in patients undergoing transcatheter tricuspid intervention.
- Integrating RA pressure with GDF-15 further refines risk stratification.
- These findings may aid in patient selection and timing of interventions.
Background:
Transcatheter tricuspid interventions for severe tricuspid regurgitation are being used increasingly, yet many patients present at an advanced stage, when clinical benefit is limited. The conventional biomarker N-terminal pro-B-type natriuretic peptide (NT-proBNP) often fails to reflect systemic organ injury or right-sided hemodynamics. We hypothesized that systemic biomarkers combined with invasive haemodynamic data improve risk stratification for 1-year mortality after transcatheter tricuspid regurgitation intervention.
Methods:
In this prospective, single-centre cohort, preprocedural blood samples for biomarker assessment (growth differentiation factor-15 [GDF-15], soluble urokinase plasminogen activator receptor [suPAR], heart-type fatty acid-binding protein [H-FABP], soluble suppression of tumorigenicity-2 [sST2}, NT-proBNP) and right atrial (RA) pressure were obtained in patients undergoing transcatheter tricuspid repair or valve implantation. Incremental prognostic value was assessed by adding RA pressure to biomarker-based models. Predictive performance for 1-year all-cause mortality was evaluated using receiver operating characteristic analyses. Optimal cutoffs were derived by Youden's index, and survival was compared using Kaplan-Meier analysis and log-rank testing.
Results:
Among 100 patients (mean age, 80.7 ± 6.7 years; 48% male), 22 (22%) died within 1 year. The cohort showed advanced disease and a high comorbidity burden. GDF-15 demonstrated the highest prognostic accuracy (area under the curve [AUC] 0.795, 95% confidence interval [CI] 0.675-0.915; P < 0.001), followed by suPAR (AUC 0.746, 95% CI 0.626-0.866; P < 0.001). NT-proBNP did not significantly predict mortality. Combining GDF-15 with RA pressure improved discrimination (AUC 0.805). An elevated level of GDF-15 or suPAR was associated with significantly reduced survival.
Conclusions:
In patients undergoing transcatheter tricuspid intervention, GDF-15 and suPAR outperform NT-proBNP in predicting 1-year mortality. Integration of RA pressure further refines risk stratification and may aid patient selection and the timing of intervention.
